NASDAQ: HSDTSolana Co Stock
$1.74+0.09 (+5.45%)
Updated Jul 1, 2026
HSDT Price
$1.74
Fair Value Price
N/A
Market Cap
$101.59M
52 Week Low
$1.19
52 Week High
$25.50
P/E
-0.07x
P/B
0.51x
P/S
13.84x
PEG
N/A
Dividend Yield
N/A
Revenue
$9.59M
Earnings
-$136.85M
Gross Margin
94.2%
Operating Margin
-1,420.59%
Profit Margin
-1,427.1%
Debt to Equity
0.01
Operating Cash Flow
-$18M
Beta
1.38
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
HSDT Overview
Solana Co. is a medical device firm specializing in neurotechnology, dedicated to improving neurological wellness. The company's strategy involves developing, licensing, and acquiring innovative, non-invasive platform technologies. These technologies are designed to enhance the brain's intrinsic capacity for self-healing and mitigate the effects of neurological diseases or trauma. A prime example of their work is the development of an investigational portable neuromodulation stimulator. This device uniquely delivers neurostimulation through the tongue. Clinical studies have indicated that this approach significantly enhances the efficacy of physical exercises for individuals experiencing neurological symptoms stemming from conditions like disease or trauma, including mild-to-moderate traumatic brain injury. Established on March 13, 2014, Solana Co. maintains its headquarters in Newtown, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HSDT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
HSDT
Ranked#47 of 94
Ranked#47 of 94
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.85 | A | |
| $44.07 | A | |
| $30.65 | A |
Be the first to know about important HSDT news, forecast changes, insider trades & much more!
HSDT News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HSDT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HSDT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HSDT is good value based on its book value relative to its share price (0.51x), compared to the US Medical Devices industry average (3x)
P/B vs Industry Valuation
HSDT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more HSDT due diligence checks available for Premium users.
Valuation
HSDT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.07x
Industry
20.03x
Market
8.54x
HSDT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.51x
Industry
3x
HSDT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HSDT's financial health
Profit margin
Revenue
$3.6M
Net Income
-$99.8M
Profit Margin
-2,756.1%
HSDT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
HSDT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$200.7M
Liabilities
$2.8M
Debt to equity
0.01
HSDT's short-term assets ($27.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HSDT's short-term assets ($27.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HSDT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
HSDT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.8M
Investing
$5.5M
Financing
-$3.5M
HSDT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HSDT vs Medical Device Stocks
Solana Co Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.